Thermo Fisher Scientific Inc (TMO) Stock Price & How to Invest

Thermo Fisher Scientific, headquartered in Waltham, Massachusetts, is a global provider of scientific instruments, consumables, reagents, and services used across pharmaceutical and biotech drug development, clinical diagnostics, academic research, and environmental and industrial testing. The company operates through four reportable segments: Life Sciences Solutions (reagents, proteins, and consumables for research and bioproduction), Analytical Instruments (mass spectrometers, chromatography systems, electron microscopes, and laboratory equipment), Specialty Diagnostics (clinical diagnostic kits and transplant diagnostics), and Laboratory Products and Biopharma Services (supply-chain distribution, contract research through PPD, and contract drug manufacturing through Patheon). Revenue is generated through instrument sales, high-margin consumables and reagents that customers repurchase continuously, long-term service contracts, and growing contract development and manufacturing (CDMO) fees; consumables and services collectively account for a majority of annual sales and provide durable recurring revenue.

Thermo Fisher Scientific was formed in 2006 through the merger of Thermo Electron and Fisher Scientific, two companies with roots stretching back decades in laboratory equipment and scientific supply. Since the merger the company has pursued an aggressive acquisition-led growth strategy, adding capabilities in clinical research (PPD, acquired 2021), contract manufacturing (Patheon), and numerous instrument and reagent franchises. Marc N. Casper has served as Chief Executive Officer since October 2009 and was elected Chairman of the Board in February 2020, giving the company unusual leadership continuity; Gianluca Pettiti serves as President and Chief Operating Officer. The leadership team has presided over a roughly four-fold increase in annual revenue since Casper took the helm, driven by both organic share gains and a disciplined mergers-and-acquisitions program funded by the company's substantial free cash flow.

The most significant near-term risk is a contraction in research funding from government agencies (including NIH) and from biotech companies whose access to capital markets has historically been cyclical; when funding tightens, customers delay instrument purchases and reduce consumable orders, pressuring organic revenue growth. Thermo Fisher's active acquisition strategy carries integration and leverage risk, particularly after committing approximately $13 billion to mergers and acquisitions in 2025 alone, and a large deal that underperforms expectations could weigh on earnings and the balance sheet simultaneously. Geopolitical friction, particularly regarding China, creates both a demand risk (softer orders from Chinese academic and industrial customers) and a supply chain risk, while tariff policy changes can disrupt cost structures. Finally, the stock's valuation, though below its own ten-year average on a trailing price-to-earnings basis, still prices in sustained mid-single-digit organic growth, leaving limited room for disappointment if end markets soften.

26 analysts publish price targets on TMO, averaging $629.50 against a $574.30 price as of August 2026, or +9.6%. The published targets run from $520.00 to $750.00, a moderate spread, and the ratings split 22 buy, 6 hold, 0 sell. Over the last six months there have been 4 raises and 7 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full TMO forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Thermo Fisher Scientific Inc. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Bioprocessing and Biologic Drug Manufacturing Tailwind. The global shift toward biologic drugs, cell and gene therapies, and mRNA-based medicines requires single-use systems, cell culture media, filtration hardware, and purification resins that Thermo Fisher supplies at scale. The most optimistic published target, $750.00, assumes this works close to its best case.

The case against. The most significant near-term risk is a contraction in research funding from government agencies (including NIH) and from biotech companies whose access to capital markets has historically been cyclical; when funding tightens, customers delay instrument purchases and reduce consumable orders, pressuring organic revenue growth. The most pessimistic target, $520.00, is roughly what TMO is worth if this bites instead.

Read the full bull and bear case on TMO, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Thermo Fisher Scientific Inc's investor relations page or your broker.

• Revenue (Full Year 2025): ~$44.6 billion
• Revenue Guidance (Full Year 2026): ~$46.3 to $47.2 billion
• Adjusted Operating Income (Full Year 2025): ~$10.1 billion
• Adjusted Operating Margin (Full Year 2025): ~22.7%
• Adjusted EPS (Full Year 2025): ~$22.87
• Adjusted EPS Guidance (Full Year 2026): ~$24.22 to $24.80
• Free Cash Flow (Full Year 2025): ~$6.3 billion
• Trailing P/E Ratio: ~26x (as of mid-2026, below the 10-year average of ~32x)
• Gross Margin (TTM): ~41%

Thermo Fisher's trailing price-to-earnings ratio of roughly 26x sits approximately 18% below its own ten-year historical average of about 32x, reflecting a period of softer organic growth as the post-pandemic diagnostics and COVID-related revenue tailwind has faded. The adjusted operating margin of 22.7% for 2025 and management guidance for 6 to 8 percent adjusted EPS growth in 2026 suggest the earnings recovery is progressing, though the pace of organic revenue acceleration remains a key variable the market is watching. Free cash flow of roughly $6.3 billion gives the company significant flexibility for continued share repurchases, dividends, and acquisitions.

If you want TMO exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

These are the investment theses TMO naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to TMO: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get TMO exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (XLV, VHT), which spreads the position across many companies. Or build it into a focused thematic portfolio, so TMO sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where TMO fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Thermo Fisher Scientific is today a consumables-and-services-led life sciences infrastructure company: its largest revenue driver is the steady cadence of reagents, single-use bioprocessing supplies, and contract research and manufacturing fees that customers re-order regardless of any single product cycle, and that engine produced approximately $44.6 billion in 2025 revenue alongside roughly $6.3 billion in free cash flow. If you believe that global pharmaceutical R&D spending, biologic drug production, and genomics-driven research will compound over the next decade, the question becomes sizing and overlap with other healthcare-tools positions, not timing; the risk is that a meaningful contraction in NIH or agency research budgets, a biotech funding drought, or integration stumbles from large acquisitions compresses both revenue growth and the valuation multiple simultaneously.

Whether TMO is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is TMO a buy or a sell?, and where the stock could go from here in the TMO stock forecast.

For income investors, whether TMO pays a dividend and how the payout looks is covered in does TMO pay a dividend? And to weigh TMO against a peer, read the full side-by-side comparisons: TMO vs ABBV and TMO vs ABT.